FEZ1/LZTS1 protein expression in ovarian cancer |
| |
| Authors: | Daniela Califano Sandro Pignata Carmela Pisano Stefano Greggi Giuseppe Laurelli Nunzia Simona Losito Alessandro Ottaiano Adolfo Gallipoli Rosa Pasquinelli Veronica De Simone Roberto Cirombella Alfredo Fusco Gennaro Chiappetta |
| |
| Institution: | 1. Istituto Nazionale dei Tumori, Napoli, Italy;2. Centro di Ricerche Oncologiche Mercogliano (CROM), Avellino, Italy;3. Divisione di Anatomia Patologica, II Facoltà di Medicina, Università “La Sapienza,” Ospedale Sant'Andrea, Roma, Italy;4. Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Napoli, Italy |
| |
| Abstract: | The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico‐pathological variables, response to chemotherapy and disease‐free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease‐free survival, or overall survival. On the contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane‐based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma. J. Cell. Physiol. 222: 382–386, 2010. © 2009 Wiley‐Liss, Inc. |
| |
| Keywords: | |
|
|
